Compare FLOC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | VOR |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | 1281 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 949.8M | 813.3M |
| IPO Year | N/A | 2021 |
| Metric | FLOC | VOR |
|---|---|---|
| Price | $19.31 | $20.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $28.50 | ★ $45.33 |
| AVG Volume (30 Days) | 831.2K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.92 | N/A |
| Revenue Next Year | $8.59 | N/A |
| P/E Ratio | $16.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.03 | $1.62 |
| 52 Week High | $28.26 | $49.95 |
| Indicator | FLOC | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 29.21 | 73.35 |
| Support Level | $17.46 | $11.62 |
| Resistance Level | $24.37 | $49.95 |
| Average True Range (ATR) | 1.03 | 1.39 |
| MACD | -0.26 | 0.64 |
| Stochastic Oscillator | 13.41 | 76.44 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.